Amgen's marketing efforts help boost Tepezza sales

Amgen’s roller coaster ride known as Tepezza is ascending again. Is the thyroid eye disease (TED) treatment finally gaining momentum that is sustainable?

In the second quarter, Tepezza generated $479 million in sales for an increase of 8% year over year and 13% sequentially. It was Tepezza’s highest quarterly sales figure since the fourth quarter of 2022.